HPV+ Cervical Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Premalignant and malignant cervix epithelial lesions, as well as varying percentage of neoplastic lesions of the vulva, vagina, anus, penis, and oropharynx, have all been linked to persistent infection with particular oncogenic HPV strains. At least 15 of the more than 100 known HPV genotypes have been linked to cervix and other cancers. In developing nations, cervical cancer affects more women than any other type of cancer. Approximately 260 000 people are said to die from it each year, with more than 80% of those deaths taking place in developing nations. Numerous studies have been conducted across the globe on the epidemiology of HPV infection and the oncogenic potential of various HPV genotypes. Recent statistical data demonstrates that using HPV vaccines is very effective for preventing infection and disease linked to the particular HPV genotypes. Numerous nations around the world have implemented vaccination programs with great success.

Description

Premalignant and malignant cervix epithelial lesions, as well as varying percentage of neoplastic lesions of the vulva, vagina, anus, penis, and oropharynx, have all been linked to persistent infection with particular oncogenic HPV strains. At least 15 of the more than 100 known HPV genotypes have been linked to cervix and other cancers. The two most prevalent oncogenic forms of HPV, 16 and 18, are responsible for 70% of all cervical malignancies worldwide. In particular, genotypes 6 and 11 of HPV can lead to genital warts. Due to its high potential for transmission, HPV is currently thought to be the STD that affects most populations most frequently. Despite the fact that most infected women test negative for the virus after two years, those who continue to have high-risk HPV infections are most at risk of developing cervical cancer. The development of novel screening programs was aided by the association between high-risk HPV types and cervical cancer development. For instance, the WHO and the European Guidelines for Quality Assurance for Cervical Cancer Screening both recommend testing for high-risk HPV as a screening tool. In particular, population-based cervical screening programs have found that HPV testing is effective in detecting precancerous cervical lesions. A new model for cervical carcinogenesis, consisting of HPV acquisition, HPV persistence, progression to precancer, and invasion, has been developed as a result of the identification of the causal relationship between HPV and cervical cancer as well as knowledge of the epidemiology and natural history of HPV infection. This model aids in the development of age-appropriate cervical cancer prevention strategies.

HPV+ Cervical Cancer (Epidemiology)

In developing nations, cervical cancer affects more women than any other type of cancer. Approximately 260 000 people are said to die from it each year, with more than 80% of those deaths taking place in developing nations. Numerous studies have been conducted across the globe on the epidemiology of HPV infection and the oncogenic potential of various HPV genotypes. The population-based incidence has not yet been determined in many nations, though. Additionally, different nations have different approaches to cervical cancer screening. Potentially more effective than opportunistic screening programs are organized cervical screening programs. With nearly 500,000 new cases each year, cervical cancer is the most common genital cancer in women worldwide. Worldwide, there were 239,000 fatal cases and 526,000 new cases of cervical cancer in 2015. Squamous cell carcinoma makes up the majority of cervical cancer cases. According to statistics from 2015 to 2019, there were 26,177 women and 21,022 men diagnosed with new HPV-associated malignancies annually in the United States. Men are more likely to develop cervical cancer than women are, in contrast to oropharyngeal malignancies, which are cancers of the base of the tongue and tonsils at the back of the throat. Over 90% of anal and cervical malignancies are thought to be caused by HPV. In different geographical areas, cervical cancer mortality varies. In developed nations, the age-standardized incidence rate for cervical cancer is much lower than in developing nations, where it is 8.0 per 100,000. Comparatively, developed countries have a lower age-standardized mortality rate for cervical cancer, at 2 points per 100,000, than developing countries, which have a higher rate of 4 points per 100,000. For instance, in 2012, there were 34,08 new cases and 22,05 deaths per 100,000 women in sub-Saharan Africa, compared to 4,08 new cases and 1,09 deaths per 100,000 women in Western Asia. Northern America has the third-lowest cervical cancer rate in the world, according to research.

HPV+ Cervical Cancer -Current Market Size & Forecast Trends

The market for HPV-positive cervical cancer is projected to grow steadily, with the global cervical cancer treatment market valued at approximately USD 8.16 billion in 2023 and expected to reach around USD 10.9 billion by 2030, reflecting a compound annual growth rate (CAGR) of 5.4% during this period. The increasing incidence of cervical cancer, primarily driven by high-risk human papillomavirus (HPV) infections, is a significant factor contributing to market growth. HPV is responsible for about 94% of cervical cancer cases, highlighting the critical need for effective screening and vaccination programs, particularly in low- and middle-income countries where access remains limited. Additionally, advancements in treatment options, including immunotherapies and targeted therapies, are enhancing patient outcomes and driving demand. The adenocarcinoma segment is expected to grow at a higher CAGR of 5.8% due to rising awareness and improved access to HPV vaccines. Overall, the HPV-positive cervical cancer market is well-positioned for growth through 2035, supported by ongoing innovations in treatment and increased health initiatives aimed at prevention and early detection.

Recent statistical data demonstrates that using HPV vaccines is very effective for preventing infection and disease linked to the particular HPV genotypes. Numerous nations around the world have implemented vaccination programs with great success. Catch-up vaccination cohorts and established registration have shown reductions in the diagnosis of CIN in screening women as a result of vaccination in developing nations with long-standing screening programs. Three commercially available vaccines are available for prophylaxis against HPV: Cervarix (a bivalent vaccine against HPV16 and HPV18), Gardasil (a tetravalent against HPV6, 11, 16, and 18), and Gardasil 9 (a 9-valent vaccine against HPV6, 11, 16, 18, 31, 33, 45, 52, and 58). They are non-infectious subunit vaccines that contain viral-like particles (VLPs) created by assembling the recombinant expression of the HPV L1 major capsid protein in yeast (Gardasil) and in insect cells (Cervarix).

Report Highlights

HPV+ Cervical Cancer - Current Market Trends

HPV+ Cervical Cancer - Current & Forecasted Cases across the G8 Countries

HPV+ Cervical Cancer - Market Opportunities and Sales Potential for Agents

HPV+ Cervical Cancer - Patient-based Market Forecast to 2035

HPV+ Cervical Cancer - Untapped Business Opportunities

HPV+ Cervical Cancer - Product Positioning Vis-a-vis Competitors' Products

HPV+ Cervical Cancer - KOLs Insight